CG Bio ramps up production with new regenerative medicine plant

CG Bio said Wednesday that its second manufacturing facility, Novo Factory, has received final regulatory approval and begun full-scale operations, strengthening the company’s production capacity for regenerative medicine. The new facility will focus on manufacturing Novosis Putty and other orthopedic surgery products, supporting the company’s expansion into advanced markets such as the United States and Japan. While CG Bio’s first plant, S-Campus, specializes in dermal filler production, Novo F

By The Korea Herald